


Supplementary Figure A. Clinical outcomes among patients receiving standard treatment. Kaplan-Meier plots show (A) disease-free survival, (B) recurrence-free survival and (C) overall survival for patients receive standard treatment. Abbreviations: EC-T, epirubicin and cyclophosphamide followed by docetaxel; No, Number.



Supplementary Figure B. Efficacy of the integrated mRNA-IncRNA signature and traditional clinicopathologic factors in determination of prognosis in the high-risk (arm B) and low-risk patients (arm C) receiving the same standard treatment. Time-dependent receiver operating curves for (A) disease-free survival (DFS), (B) recurrence-free survival (RFS) and (C) overall survival (OS) were plotted with AUCs reported. All factors were coded as categorical variables.

Supplementary Table A. Participating centers.				
Number	Hospital			
1	Fudan University Shanghai Cancer Center			
2	Chongqing Cancer Hospital, Chongqing University			
3	Northern Jiangsu People's Hospital			
4	Fujian Medical University Union Hospital			
5	Shanghai First Maternity and Infant Hospital			
6	Obstetrics and Gynecology Hospital of Fudan University			
7	The International Peace Maternity & Child Health Hospital of China Welfare Institute			

	Arm A (n = 163) TEC-GP N (%)	Arm B (n = 169) EC-T N (%)	Difference (95% CI)
Patients who completed all planned cycles of treatment	149 (91)	158 (93)	-2 (-8 to 4)
Any treatment-related adverse events (TRAEs)	163 (100)	169 (100)	0 (-2 to 2)
Any ≥3 TRAEs	105 (64)	86 (51)	13 (3 to 24)
Treatment-related SAEs	9 (6)	7 (4)	2 (-4 to 6)
Any TRAEs leading to dose delayed	47 (29)	33 (20)	9 (0 to 18)
Any TRAEs leading to dose reduction	51 (31)	25 (15)	16 (7 to 25)
Any TEAEs leading to drug permanently discontinued	8 (5)	5 (3)	2 (-3 to 7)

Supplementary Table B. Treatment cycles and dose modifications between arm A and arm B in high-risk patients.

Abbreviations: CI, confidence interval; EC-T, epirubicin and cyclophosphamide followed by docetaxel; TEC-GP, docetaxel, epirubicin, and cyclophosphamide followed by gemcitabine and cisplatin. SAE, severe adverse event. TRAE, Treatment-related adverse event.